Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Biota is a world-leading antiviral drug discovery company with its headquarters in Melbourne, Australia. Biota’s first breakthrough was the discovery of zanamivir, the first neuraminidase inhibitor, subsequently marketed by GlaxoSmithKline as Relenza for the treatment of influenza. In partnership with Thermo Electron, Biota markets the FLU OIA® diagnostics range for the rapid detection of influenza. In partnership with Sankyo, Biota is engaged in the development of second generation flu antivirals (LANI or Long Acting Neuraminidase Inhibitors). Biota also has active discovery and development programs aimed at new therapies for diseases caused by Human Rhinovirus (common cold), RSV (Respiratory Syncytial Virus), HIV, and hepatitis C. ( www.biota.com.au )
Biota Holdings Limited
Unit 10 585 Blackburn Road
Notting Hill, Victoria 3168
AUSTRALIA
Tel: +61 3 9915 3700